Skip to main content

pitavastatin

Generic: PITAVASTATIN CALCIUM·Brand: LIVALO, Livalo, NIKITA, Nikita, PITAVASTATIN CALCIUM, Zypitamag

pitavastatin: 4 clinical trials tracked.

pitavastatin evidence translation

What we can confirm

4 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about pitavastatin, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence5 indications · 3 study sponsors
Clinical Trials (4)

A Phase 1 Study to Evaluate the Effect of Multiple Doses of ABBV-722 on the Pharmacokinetics of Cocktail Probe Substrates of CYP3A and Select Transporters in Healthy Adult Subjects

NCT07567781·Phase 1·ABBV
Completed

Primary endpoint: Number of Participants with Adverse Events (AEs)

Interventionalopen12 enrolledStarted 2026-04Completion 2026-071 site · United StatesAbbVie

An Open-Label, Fixed-Sequence Study to Evaluate the Effect of Etavopivat on the Single-Dose Pharmacokinetics of Midazolam, Digoxin, Rosuvastatin, Pitavastatin, and Metformin in Healthy Adult Participants

NCT06813924·Phase 1·NVO
Completed

Primary endpoint: Cmax, digoxin, SD: Maximum observed digoxin plasma concentration with and without etavopivat at steady state

Interventionalopen37 enrolledStarted 2025-02Completion 2025-051 site · United StatesNovo Nordisk A/S

A Phase 1 Open-Label, Dose Escalation Study of Pitavastatin in Combination With Venetoclax in Patients With Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia

NCT04512105·Phase 1·UTHR
Completed

Primary endpoint: Maximum Tolerated Dose for PIT administered with VEN-containing Standard of Care (SOC) regimens

Interventionalopen6 enrolledStarted 2020-12Completion 2025-021 site · United StatesUniversity of California, Irvine

Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE

NCT02344290·Phase 3
Completed

Primary endpoint: Incidence Rate of Major Adverse Cardiovascular Event (MACE)

InterventionalRandomizedquadruple7,769 enrolledStarted 2015-03Completion 2023-0850 sites · United StatesNational Institute of Allergy and Infectious Diseases (NIAID)